Clinical Scorecard: Case Study: Preserving Vision in Geographic Atrophy with Complement Inhibitor Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) in age-related macular degeneration |
| Key Mechanisms | Complement inhibitor therapy slows progression of GA by targeting complement pathway |
| Target Population | Patients with GA exhibiting lesion growth and functional vision decline, especially those reliant on a better-functioning eye |
| Care Setting | Specialized ophthalmology and retina clinics with access to multimodal imaging and intravitreal injection therapy |
Key Highlights
- Complement inhibitor therapy transforms GA management from observation to proactive treatment.
- Therapy slows lesion growth by approximately 20-30% over 2-3 years but does not restore lost vision.
- Flexible dosing (monthly or every-other-month) allows balancing efficacy with reduced side effects.
Guideline-Based Recommendations
Diagnosis
- Confirm GA diagnosis and progression using multimodal imaging including OCT and fundus autofluorescence.
- Identify hyperfluorescent lesion edges as a hallmark of progression.
Management
- Initiate complement inhibitor therapy in patients with progressive GA and functional vision impairment.
- Begin treatment cautiously, starting with the poorer eye to monitor for inflammation or vasculitis before treating the better-functioning eye.
- Prefer every-other-month dosing to reduce treatment burden and minimize dose-dependent risks.
Monitoring & Follow-up
- Perform regular imaging to assess lesion growth and monitor for adverse effects.
- Monitor for intraocular inflammation and conversion to wet AMD during therapy.
Risks
- Potential for intraocular inflammation.
- Risk of conversion to wet age-related macular degeneration.
Patient & Prescribing Data
Older adults with GA and functional vision decline, especially those with one better-functioning eye.
Treatment aims to delay foveal involvement and preserve vision quality; efficacy demonstrated in phase 3 trials (OAKS, DERBY, GALE) with 20-30% slowing of lesion growth.
Clinical Best Practices
- Use multimodal imaging to confirm GA progression before initiating therapy.
- Start treatment in the poorer eye to assess safety before treating the better eye.
- Opt for every-other-month dosing to balance efficacy and safety.
- Educate patients that therapy slows progression but does not restore lost vision.
- Regularly monitor for adverse events including inflammation and wet AMD conversion.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
